Acta Scientific Microbiology (ASMI) (ISSN: 2581-3226)

Commentary Volume 3 Issue 9

Remdesivir and Hydroxychloroquine: An Important First Step of Searching for Evidence to Prevent COVID-19 (SARS-CoV-2)

Indranil Chatterjee1*, Toumica Ghosh1, Sanchari Chatterjee1, Suman Kumar Nath1, Rakhi Bakuli2 and Soumitra Sahana3

1Assistant Professor, Birbhum Pharmacy School, Birbhum, West Bengal, India
2Assistant Professor, P.G Institute of Medical Sciences, Chandrakona Town, Paschim Midnapore, West Bengal, India
3B. Pharm, Birbhum Pharmacy School, Birbhum, West Bengal, India

*Corresponding Author: Indranil Chatterjee, Assistant Professor, Birbhum Pharmacy School, Birbhum, West Bengal, India.

Received: July 06, 2020; Published: August 18, 2020


Extreme intense respiratory disorder coronavirus 2 (SARS-CoV-2), the infection that causes coronavirus illness 2019 (Covid-19), has created an overall pandemic. The interference of its spread relies upon a blend of pharmacologic and nonpharmacologic intercessions. Beigel., et al. have given in the Journal the principal report of a powerful treatment for Covid-19, coming about because of a thoroughly structured and led clinical trial [1].

It is surprising that a randomized, fake treatment controlled preliminary of a possible antiviral treatment for an infection whose pathogenesis is as yet not completely characterized was done at numerous global locales during a pandemic.



  1. Beigel JH., et al. “Remdesivir for the treatment of Covid-19 — preliminary report”. The New England Journal of Medicine (2020).
  2. FDA issuance of emergency use authorization for potential COVID-19 treatment. Press release of the Food and Drug Administration (2020).
  3. Goldman JD., et al. “Remdesivir for 5 or 10 days in patients with severe Covid-19”. The New England Journal of Medicine (2020).
  4. Guan W., et al. “Clinical characteristics of coronavirus disease 2019 in China”. The New England Journal of Medicine 382 (2020): 1708-1720.
  5. Mehta P., et al. “COVID-19: consider cytokine storm syndromes and immunosuppression”. Lancet 395 (2020): 1033-1034.
  6. Cohen MS and Corey L. “Combination prevention for COVID-19”. Science 368 (2020): 551.
  7. Rolain J-M., et al. “Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century”. International Journal of Antimicrobial Agents 30 (2007): 297-308.
  8. Yao T-T., et al. “A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus — a possible reference for coronavirus disease-19 treatment option”. Journal of Medical Virology 92 (2020): 556-563.
  9. Hernandez AV., et al. “Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review”. Annals of Internal Medicine (2020).
  10. Boulware DR., et al. “A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19”. The New England Journal of Medicine (2020).
  11. Tostmann A., et al. “Strong associations and moderate predictive value of early symptoms for SARSCoV-2 test positivity among healthcare workers, the Netherlands, March 2020”. Euro Surveillance 25.16 (2020): 2000508.
  12. Wu Z and McGoogan JM. “Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention”. JAMA (2020).
  13. Sheahan TP., et al. “An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice”. Science Translational Medicine 12.541 (2020): eabb5883.
  14. Magagnoli J., et al. “Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19” (2020). 
  15. Sayare S. “He was a science star. Then he promoted a questionable cure for COVID-19”. New York Times Magazine (2020).


Citation: Indranil Chatterjee., et al. “Remdesivir and Hydroxychloroquine: An Important First Step of Searching for Evidence to Prevent COVID-19 (SARS-CoV-2)". Acta Scientific Microbiology 3.9 (2020): 23-26.


Acceptance rate30%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 30th, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue".
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US